top of page
CSTI-500 has the potential to provide a transformative therapy, not just for addressing hyperphagia in PWS, but also for tackling many of the associated psychiatric co-morbidities.

CSTI-500

Triple Monoamine Reuptake Inhibitor for the treatment of hyperphagia and other neurobehavioral challenges in Prader-Willi Syndrome.

Read More

CSTI-100 / HBS-102

MCHR1 antagonist for the treatment of rare neurological disorders.

Read More
bottom of page